Investigational Janus kinase inhibitors in development for myelofibrosis.

Abstract excerpt

INTRODUCTION: Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the only one currently available for treatment of myelofibrosis, with many others having been discontinued for toxicity, and considerable uncertainty surrounding the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to Drugs, Investigational
• Share to JAK1 gene